NL-OMON51516
Recruiting
Not Applicable
A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of MK-1484 as a Monotherapy and in Combination with Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors - MK1484-001
Merck Sharp & Dohme (MSD)0 sites30 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Advanced or Metastatic Solid Tumors / Terminal cancer
- Sponsor
- Merck Sharp & Dohme (MSD)
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\# The participant has provided documented informed consent for this study.
- •\# Male or female of at least 18 years at the time of signing the informed
- •consent form.
- •\# Histologically\- or cytologically\-confirmed advanced/metastatic solid tumor by
- •pathology report and received, or intolerant to, all treatment known to confer
- •clinical benefit.
- •\# Measurable disease by RECIST 1\.1\.
- •\# Performance status of 0 or 1 on the ECOG Performance Scale (within 7 days
- •before the start of study intervention).
- •\# Normal cardiac function based on TTE or MUGA.
Exclusion Criteria
- •\# Chemotherapy, definitive radiation or biological cancer therapy within 4
- •weeks (2 weeks for palliative radiation) before the first dose of study
- •intervention.
- •\# Not recovered to CTCAE Grade 1 or better from any AEs that were due to cancer
- •therapeutics administered more than 4 weeks earlier.
- •\# Currently participating and receiving study intervention in a study of an
- •investigational agent, or participated and received study intervention in a
- •study of an investigational agent, or used an investigational device within 28
- •days of administration of MK\-1484\.
- •\# Received any prior IL\-2 based therapy.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 Alone and in Combination with Palbociclib in Women with Estrogen Receptor Positive, HER2-Negative Advanced Breast CancerNL-OMON50738G1 Therapeutics Inc.45
Unknown
Phase 1
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, PK and Preliminary Anti-tumor Activity when given as a monotherapy of Tremelimumab or Tremelimumab in combination with MEDI4736 in Japanese Patients with Advanced Solid Malignancies, and when given as a monotherapy of tremelimumab in Second- or Third-line Treatment of Japanese Subjects with Unresectable Pleural or Peritoneal Malignant MesotheliomaJPRN-jRCT2080222502AstraZeneca
Completed
Phase 1
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 uUnder Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies.Advanced Solid Malignancy, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial CancerJPRN-jRCT2080222792AstraZeneca KK25
Unknown
Phase 1
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD1208 in Patients With Advanced Solid Malignancies Including Malignant LymphomaAdvanced Solid Malignancies, Malignant LymphomaJPRN-jRCT2080221904AstraZeneca
Completed
Phase 1
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered to Japanese Patients With Advanced Solid MalignanciesJPRN-jRCT2080222811AstraZeneca